


Supplementary Table 1. Characteristics of HZ cases among JAKi users

	Age	Gender	Duration of treatment with JAKi*		MTX	History of treatment with bDMARD	HZ vaccination
			until HZ development	total			
Patient 1	63	female	9.4	9.9	yes	no	yes
Patient 2	63	female	8.8	11.8	yes	no	no
Patient 3	60	female	32.1	37.0	yes	yes	no
Patient 4	39	female	5.0	5.6	no	no	no
Patient 5	57	female	11.2	20.2	yes	yes	yes
Patient 6	45	female	21.5	26.6	yes	yes	no
Patient 7	54	female	12.2	20.9	yes	no	no
Patient 8	72	female	5.1	16.2	yes	no	no
Patient 9	69	female	4.7	16.2	yes	no	no
Patient 10	72	female	4.5	18.8	yes	yes	no
Patient 11	57	female	6.7	22.5	no	yes	no
Patient 12	66	female	12.6	31.6	yes	no	no
Patient 13	57	male	10.5	25.6	no	yes	no
Patient 14	69	female	9.9	28.1	yes	yes	no
Patient 15	63	female	1.8	23.0	yes	yes	no
Patient 16	60	female	2.7	27.9	yes	yes	no
Patient 17	36	female	2.7	38.8	yes	yes	no

HZ, herpes zoster; JAKi, Janus kinase inhibitor; MTX, methotrexate; bDMARD, biologic disease-modifying antirheumatic drug.

*Values are presented as months. Each values are duration from the initiation of JAKi to HZ development, and to the end of medication use within the observation period.



Supplementary Figure 1. Number of cases diagnosed with herpes zoster by age group

JAKi, Januse kinase inhibitor; bDMARD, biologic disease-modifying antirheumatic drug